India's market for obesity and diabetes drugs is experiencing a slowdown, a stark contrast to the initial surge seen with the introduction of generic semaglutide products. This cooling trend suggests that the early excitement may have been a temporary phenomenon.

The rapid influx of cheaper generic alternatives initially boosted sales volumes, but this momentum appears to be waning. The market may be facing challenges related to sustained demand, pricing pressures, or increased competition beyond just generic availability.

This development impacts pharmaceutical companies operating in India, particularly those relying on the GLP-1 receptor agonist class of drugs, which includes semaglutide. Investors and businesses need to reassess growth projections for this segment, considering the potential for a more normalized, slower growth trajectory rather than the explosive expansion initially anticipated.